Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B.
FASI
MEK inhibitor
NF1
low grade glioma
selumetinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Mar 2023
31 Mar 2023
Historique:
received:
16
02
2023
revised:
15
03
2023
accepted:
21
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Understanding the effect of selumetinib on FASI may help elucidate the biology, proliferative potential, and role in neurocognitive changes for these NF1-associated lesions. Patients with NF1-associated LGG and FASI treated with selumetinib on PBTC-029B were age-matched to untreated patients with NF1-associated FASI at Cincinnati Children's Hospital Medical Center. Paired bidirectional measurements were compared over time using nonparametric tests. Sixteen age-matched pairs were assessed (age range: 2.8-16.9 years, 60% male). Initial FASI burden was not different between groups (median range 138.7 cm Treatment with selumetinib did not affect the overall FASI size in children with NF1 treated for progressive low-grade glioma.
Sections du résumé
BACKGROUND
BACKGROUND
Understanding the effect of selumetinib on FASI may help elucidate the biology, proliferative potential, and role in neurocognitive changes for these NF1-associated lesions.
METHODS
METHODS
Patients with NF1-associated LGG and FASI treated with selumetinib on PBTC-029B were age-matched to untreated patients with NF1-associated FASI at Cincinnati Children's Hospital Medical Center. Paired bidirectional measurements were compared over time using nonparametric tests.
RESULTS
RESULTS
Sixteen age-matched pairs were assessed (age range: 2.8-16.9 years, 60% male). Initial FASI burden was not different between groups (median range 138.7 cm
CONCLUSIONS
CONCLUSIONS
Treatment with selumetinib did not affect the overall FASI size in children with NF1 treated for progressive low-grade glioma.
Identifiants
pubmed: 37046770
pii: cancers15072109
doi: 10.3390/cancers15072109
pmc: PMC10092996
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : UM1 CA081457
Pays : United States
Références
Eur J Paediatr Neurol. 2012 Jan;16(1):42-7
pubmed: 22088602
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486389
N Engl J Med. 2016 Dec 29;375(26):2550-2560
pubmed: 28029918
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
Neurology. 2013 May 14;80(20):e215-6
pubmed: 23671349
Cerebellum Ataxias. 2018 Oct 30;5:13
pubmed: 30410778
Neurol Genet. 2021 Aug 06;7(5):e616
pubmed: 34377779
Pediatr Neurosurg. 2013;49(1):55-9
pubmed: 24192157
AJNR Am J Neuroradiol. 2020 Sep;41(9):1733-1739
pubmed: 32816766
Neuro Oncol. 2017 Jun 1;19(6):750-761
pubmed: 27683733
Radiology. 1995 Jun;195(3):721-4
pubmed: 7754001
J Pediatr. 2015 Oct;167(4):851-856.e1
pubmed: 26233602
Dev Neuropsychol. 2009;34(6):736-48
pubmed: 20183730
Dev Med Child Neurol. 2012 Jan;54(1):49-51
pubmed: 22107256
Neurology. 1997 Apr;48(4):1121-7
pubmed: 9109916
J Child Neurol. 2004 Nov;19(11):853-8
pubmed: 15658789
Acta Neuropathol. 2021 Apr;141(4):605-617
pubmed: 33585982
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Cureus. 2021 Dec 21;13(12):e20561
pubmed: 35103140
Am J Med Genet A. 2004 Aug 30;129A(2):113-9
pubmed: 15316979
Pediatrics. 1999 Oct;104(4):e49
pubmed: 10506274
Neurology. 1996 Jun;46(6):1660-8
pubmed: 8649566
J Invest Dermatol. 2015 Mar;135(3):904-906
pubmed: 25354145
Eur J Paediatr Neurol. 2020 Sep;28:89-100
pubmed: 32893091
Neurol Clin Pract. 2018 Aug;8(4):283-291
pubmed: 30140579
Expert Rev Neurother. 2014 Oct;14(10):1139-52
pubmed: 25161109
Am J Med Genet A. 2014 Mar;164A(3):661-5
pubmed: 24357578
Neurology. 2005 Oct 11;65(7):1037-44
pubmed: 16217056
Pediatr Radiol. 2006 Oct;36(10):1048-56
pubmed: 16912896
Acta Paediatr. 2010 Nov;99(11):1657-60
pubmed: 21039823
Magn Reson Imaging. 2001 Oct;19(8):1081-9
pubmed: 11711232
Pediatr Neurol. 2002 Aug;27(2):123-7
pubmed: 12213613
Neurology. 2017 Apr 18;88(16):1584-1589
pubmed: 28330960
Neuroimage Clin. 2014 Apr 13;4:649-58
pubmed: 24936416
Cancers (Basel). 2021 Apr 12;13(8):
pubmed: 33921292
BMC Cancer. 2019 Dec 27;19(1):1250
pubmed: 31881853